| 中文名称 | 表柔比星 |
|---|---|
| 中文别名 | 表阿霉素;表柔比星(表阿霉素);表比星;表柔比星;表阿霉霉;(8S,10S)-10-[(3'-氨基-2',3',6'-三脱氧-alpha-L-阿拉伯吡喃糖基)-O-]-6,8,11-三羟基-8-羟乙酰基-1-甲氧基-7,8,9,10-四氢并四苯-5,12-二酮;表柔吡星;10-[(3-氨基-2,3,6-三脱氧-Α-L-阿式-己吡喃糖基)氧]-7,8,9,10-四氢-6,8,11-三羟基-8-(羟乙酰基)-甲氧基-(8S-CIS)-并四苯-5,12-二酮;表柔比星、表阿霉素、表比星 |
| 英文名称 | Epirubicin |
| 英文别名 | Epirubicin;10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8s-)oxy)-9;4’-epiadriamycin;epi-dx;imi28;5,12-Naphthacenedione, 10-(3-amino-2,3,6-trideoxy-.alpha.-L-arabino-hexopyranosyl)oxy-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-;5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-a-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-;Epi-doxorubicin;4'-epiadriamycin;4'-Epi-DX;Adriblastin;Epiadriamycin;Farmarubicin;farmorubicin;Pidorubicin;WP 697;5,12-Naphthacenedione,10-[(3-amino-2,3,6-trideoxy-a-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,(8S,10S)- (9CI);5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-a-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,(8S-cis)-;4'-Epidoxorubicin;4'-epi-Adriamycin;4'-epi-Doxorubicin;Epidoxorubicin;Farmarubicine;NSC 256942;Pharmarubicin;(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione;(8S-cis)-10-((3-Amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione;Ellence;EPIRUBICIN [WHO-DD];4' Epi Adriamycin;Pidorubicinum (Latin);AB00698552-14;EPIRUBICIN [INN];AB00698552_15;Epirubicina (INN-Spanish);DM6;Epirubicine [INN-French];Epirubicin [INN:BAN];(8S,10S)-10-{[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione;Epirubicina [Spanish];Epirubicinum [Latin];Pidorubicinum;4' Epidoxorubicin;BRD-K04548931-003-16-5;Epirubicin free base;EPIRUBICIN [VANDF];4' Epi DXR;DTXSID0022987;NCGC00263918-08;HY-13624;4-Epidoxorubicin;Epirubicinum [INN-Latin];Acid, 8;D07901;EPIRUBICIN [HSDB];3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside;(8S,10S)-10-(((2R,4S,5R,6S)-4-Amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione;AB00698552-11;DM2;Q425122;Epirubicina [INN-Spanish];UNII-3Z8479ZZ5X;Epirubicine;BRN 1445813;5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-;5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy-7,8,9,10-tetrahydro -6,8,(8S-cis)-;NSC-256942;Pidorubicina [INN-Spanish];(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside;IMI 28;(7S,9S)-7-[(2R,4S,5R,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy... |
| CAS No. | 56420-45-2 |
| 分子式 | C27H29NO11 |
| 分子量 | 543.52 |
4-(2-((2R,3R)-3-(2,5-二氟苯基)-3-羟基-4-(1H-1,2,4-三唑-1-基)丁-2-基)噻唑-4-基)苯甲腈
N-(丁基磺酰基)-O-[4-(4-哌啶基)丁基]-L-酪氨酸盐酸盐一水合物
2-(4-(1-羟基-4-(4-(羟基二苯基甲基)哌啶-1-基)丁基)苯基)-2-甲基丙酸
7-环戊基-N,N-二甲基-2-((5-(哌嗪-1-基)吡啶-2-基)氨基)-7H-吡咯并[2,3-d]嘧啶-6-甲酰胺
(1-((2R,3R,4S,5R)-3,4-二羟基-5-甲基四氢呋喃-2-基)-5-氟-2-氧代-1,2-二氢嘧啶-4-基)氨基甲酸戊酯
((3S,5R)-5-((1H-1,2,4-三唑-1-基)甲基)-5-(2,4-二氟苯基)四氢呋喃-3-基)甲基 4-甲基苯磺酸酯
N-(3-氯-4-氟苯基)-7-甲氧基-6-(3-吗啉-4-丙氧基)喹唑啉-4-胺
(6R,7R)-3-甲基-7-[(R)-2-氨基-2-苯乙酰氨基]-8-氧-5-硫杂-1-双环[4.2.0]辛-2-烯-2-甲酸
(2R,3S,5S)-3-苄氧基-5-[2-[[(4-甲氧基苯基)二苯基甲基]氨基]-6-苄氧基-9H-嘌呤-9-基]-2-苄氧基甲基环戊醇
(2R,3R,4S,5R)-2-(4-氨基吡咯并[2,1-F][1,2,4]三嗪-7-基)-3,4-二羟基-5-(羟甲基)四氢呋喃-2-甲腈
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。
CopyRight @2025 广东元丰化学试剂有限公司 版权所有 | 隐私政策 条款及条件 | 粤ICP备2025403430号-1
技术支持:库价化学